Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Carey Anders, MD
Duke Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of California San Francisco
San Francisco, California, United States
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
- University of Michigan Health System
Ann Arbor, Michigan, United States
- Washington University in St. Louis
St Louis, Missouri, United States
- Duke University Medical Center
Durham, North Carolina, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
- Providence Portland Medical Center
Portland, Oregon, United States
- Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 23 Mar 2023
- Primary completion
- 30 Nov 2026
- Completion
- 30 Nov 2027
- Last update posted
- 23 Jun 2026
- Registered enrollment
- 48
- Registry id
- NCT05323955
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.